Med­i­cines Co ex­ecs grab a $33M A round to spin out an in­fec­tious dis­ease out­fit with a pipeline

Turns out, Melin­ta didn’t bag all of The Med­i­cines Com­pa­ny’s in­fec­tious dis­ease work when they ex­e­cut­ed a buy­out deal last fall. There were some pre­clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER